Secondary APS (Anti-Phospholipid Syndrome) The Clotting Culprit Behind Autoimmune Chaos

ABSTRACT

Problem: Secondary antiphospholipid syndrome (APS) is a serious autoimmune condition occurring in association with diseases like systemic lupus erythematosus, characterized by a persistent hypercoagulable state. It leads to recurrent arterial and venous thrombosis, including deep vein thrombosis, pulmonary embolism, and stroke, often at a young age. A major clinical problem is obstetric morbidity, with recurrent miscarriages, fetal loss, and placental insufficiency. Despite thrombosis, patients may paradoxically have thrombocytopenia, complicating management. Multisystem involvement is common, affecting the brain, heart, skin, and kidneys. Cardiac manifestations such as Libman–Sacks endocarditis can occur. Neurological complications include seizures and cognitive dysfunction. The coexistence with underlying autoimmune disease increases inflammation and worsens prognosis. In severe cases, catastrophic APS can develop, leading to rapid multiorgan failure. Overall, secondary APS represents a complex interplay of autoimmunity and thrombosis, posing significant diagnostic and therapeutic challenges.

Approach: We describe clinicopathological case of a 34-year-old female presented with generalized weakness and polyarthralgia since 1 month, insidious in onset and gradually progressive, no photosensitivity, no oral ulcers, no rashes, no alopecia, no thrombotic events, and no obstetric history (recurrent abortions). Joint involvement was symmetric, no skin changes (malar rash, livedo reticularis), no lymphadenopathy, and no signs of systemic involvement. Initial investigations were done include CBC (for anemia, thrombocytopenia), ESR/CRP, renal and liver function tests, and urine routine. Autoimmune workup done include ANA, anti-dsDNA, complement levels, and antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-β2 glycoprotein I). Evaluated for thrombosis with doppler imaging and MRI brain. Assessed organ involvement such as renal (proteinuria) and CNS features. Management depended on cause, including immunosuppressants for SLE and anticoagulation as APS was confirmed. Early diagnosis is crucial to prevent complications like thrombosis and organ damage.

Findings: Laboratory findings in this case demonstrated significant hematological and immunological abnormalities consistent with secondary antiphospholipid syndrome in systemic lupus erythematosus. The complete blood count revealed anemia with hemoglobin of 8 g/dl, leukopenia with a total leukocyte count of 3.57 ×10³/µl, and borderline thrombocytopenia (143 ×10³/µl). Coagulation studies showed a normal PT/INR but prolonged PTT-LA (48.1 sec) and dRVVT (66.2 sec), which did not correct on mixing, confirming the presence of lupus anticoagulant. Autoimmune profiling revealed strongly positive ANA (1:80, homogeneous pattern) along with strongly positive anti-dsDNA, nucleosome, and histone antibodies, while SmD1, U1-snRNP, and Ku antibodies were weakly positive. Complement levels showed reduced C3 (0.84 g/l), indicating active immune complex-mediated disease, while C4 was within near-normal range. These findings collectively support active SLE with secondary APS, characterized by cytopenias, autoantibody positivity, hypocomplementemia, and laboratory evidence of lupus anticoagulant contributing to a prothrombotic state.

Conclusion: The case highlights secondary antiphospholipid syndrome occurring in a patient with newly diagnosed systemic lupus erythematosus presenting with thrombotic complications. The presence of lupus anticoagulant along with clinical features emphasizes the importance of early screening for antiphospholipid antibodies in young patients with stroke. Timely diagnosis is crucial as secondary APS significantly increases the risk of recurrent arterial and venous thrombosis. Recognition of associated immunological abnormalities helps guide appropriate management including anticoagulation and immunosuppressive therapy. Regular follow-up with repeat antibody testing is necessary to confirm persistence and guide long-term treatment. Early intervention can substantially reduce morbidity and prevent recurrence in such patients.

Keywords: Antiphospholipid Syndrome, Secondary APS, Systemic Lupus Erythematosus, Lupus Anticoagulant, Hypercoagulable State, Autoimmune Disorder, Thrombosis.

How to cite this article: Saxena A, Kale SD, Manharlal DJ, Singh N, Dash AK. Secondary APS (Anti-Phospholipid Syndrome) The Clotting Culprit Behind Autoimmune Chaos. Int J Drug Deliv Technol. 2026;16(29s):17-21. DOI: 10.25258/ijddt.16.29s.4

Source of support: Nil.

Conflict of interest: The authors declare no conflict of interest.